A method of identification of cells that show sensitivity to modulation of signaling mediated by a Fibroblast Growth Factor Receptor or a variant thereof

Details for Australian Patent Application No. 2008220821 (hide)

Owner Novartis AG

Inventors Graus Porta, Diana; Garcia-Echeverria, Carlos; Guagnano, Vito

Agent Davies Collison Cave

Pub. Number AU-B-2008220821

PCT Pub. Number WO2008/104523

Priority 07103094.4 27.02.07 EP

Filing date 25 February 2008

Wipo publication date 4 September 2008

Acceptance publication date 13 September 2012

International Classifications

G01N 33/574 Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

20 August 2009 PCT application entered the National Phase

  PCT publication WO2008/104523 Priority application(s): WO2008/104523

13 September 2012 Application Accepted

  Published as AU-B-2008220821

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008220828-Method and device for visually assisting a catheter application

2008220800-Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-( 4-morpholin-4-ylmethyl-phenyl)-isoxazo le-3-carboxylic acid ethylamide and formulations comprising these forms